In my role as Vice President, Global Clinical Head, Haematology, I lead clinical development strategy and trial execution for molecules intended to treat blood cancers, including study design and implementation, data analysis and presentation, and regulatory submissions.
I have dedicated my career to developing new therapies for cancer, with a particular focus in haematologic malignancies. I completed a fellowship in haematology/oncology at Stanford University Hospital and in the years since, I have led Phase I through Phase III clinical development strategies across a number of blood cancers including chronic lymphocytic leukaemia, mantle cell lymphoma, Waldenström’s macroglobulinaemia, hairy cell leukaemia and multiple myeloma.
Despite significant gains in the field of haematology in recent years, there are still critical unmet medical needs facing this diverse and complex family of cancers. These gaps in treating and caring for patients with blood cancer are what drives my team: we’re constantly looking at how we can apply learnings from the evolving science to our clinical research, including novel combinations of our molecules across multiple mechanisms of action.
Collaboration with AstraZeneca colleagues and with renowned cancer specialists and researchers around the world to develop new, transformative therapies and therapeutic approaches has been deeply rewarding. I’m inspired by what we’ve achieved and am excited about what the future holds as we work to deliver a new generation of medicines that could redefine how people live with blood cancers.
I have authored 25 scientific papers in haematology and oncology and am a member of the American Society of Clinical Oncology, American Society of Hematology, and the American Medical Association. After receiving both an undergraduate degree and Masters in Public Health from Johns Hopkins University, I earned a medical degree from the University of Vermont College of Medicine. In addition to a haematology/oncology fellowship, I also completed a residency in internal medicine and served as chief resident at Stanford University Hospital.
I am incredibly proud of our clinical development team’s work in advancing a molecule that is now approved in two blood cancers and being researched in multiple others, and to know that it’s making a difference in the lives of so many patients. But, our work is just getting started: our team is relentlessly exploring combination strategies and new molecules to address unmet medical needs in haematology. I am inspired by the fierce determination of my colleagues to find new solutions aimed at transforming the lives of people with blood cancer.
Appointed Vice President, Head of Haematology Clinical Development, AstraZeneca
Named Executive Director, Head of Clinical Development at Acerta
Joined Acerta Pharma, a member of the AstraZeneca Group, as Senior Medical Director
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Salles G, Wierda WG, Izumi R, Munugalavadla V, Patel P, Wang MH, Wong S, Byrd JC. Lancet. 2020 Apr 18;395(10232):1278-1291. doi: 10.1016/S0140-6736(20)30262-2.
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Ghia P, Pluta A, Wach M, Lysak D, Kozak T, Simkovic M, Kaplan P, Kraychok I, Illes A, de la Serna J, Dolan S, Campbell P, Musuraca G, Jacob A, Avery E, Lee JH, Liang W, Patel P, Quah C, Jurczak W. J Clin Oncol. 2020 Sep 1;38(25):2849-2861. doi: 10.1200/JCO.19.03355.
Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib
Alsadhan A, Cheung J, Gulrajani M, Gaglione EM, Nierman P, Hamdy A, Izumi R, Bibikova E, Patel P, Sun C, Covey T, Herman SEM, Wiestner A. Clin Cancer Res. 2020 Jun 15;26(12):2800-2809. doi: 10.1158/1078-0432.CCR-19-3505.
Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma
Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn JK, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Jain P, Frigault MM, Izumi R, Nguyen D, Patel P, Yin M, Długosz-Danecka M. Leukemia. 2019 Nov;33(11):2762-2766. doi: 10.1038/s41375-019-0575-9.
Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study
Owen RG, McCarthy H, Rule S, D'Sa S, Thomas SK, Tournilhac O, Forconi F, Kersten MJ, Zinzani PL, Iyengar S, Kothari J, Minnema MC, Kastritis E, Aurran-Schleinitz T, Cheson BD, Walter H, Greenwald D, Chen DY, Frigault MM, Hamdy A, Izumi R, Patel P, Wei H, Lee SK, Mittag D, Furman RR. Lancet Haematol. 2020 Feb;7(2):e112-e121. doi: 10.1016/S2352-3026(19)30210-8.
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn J, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Covey T, Dua R, Hamdy A, Huang X, Izumi R, Patel P, Rothbaum W, Slatter JG, Jurczak W. Lancet. 2017 Dec 11. S0140-6736(17)33108-2. doi: 10.1016/S0140-6736(17)33108-2.
Acalabrutinib with Obinutuzumab in Relapsed/Refractory and Treatment-Naive Patients with Chronic Lymphocytic Leukemia: The Phase 1b/2 ACE-CL-003 Study
Woyach JA, Awan FT, Jianfar M, Rogers KA, Jones J, Covey T, Hamdy A, Izumi R, Patel P, Wang MH, Byrd JC. Blood 2017;130 (Supplement 1): 432. doi: https://doi.org/10.1182/blood.V130.Suppl_1.432.432.